First 10 transcatheter pulmonary valve-in-valve procedures in rajaie cardiovascular medical and research center

IF 0.2 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS
S. Abdi, A. Firouzi, M. Alemzadeh-Ansari, Zahra Hosseini, A. Alizadehasl, Z. Khajali, S. Saedi, Nima Salehi, B. Koohestani, E. Khalilipur
{"title":"First 10 transcatheter pulmonary valve-in-valve procedures in rajaie cardiovascular medical and research center","authors":"S. Abdi, A. Firouzi, M. Alemzadeh-Ansari, Zahra Hosseini, A. Alizadehasl, Z. Khajali, S. Saedi, Nima Salehi, B. Koohestani, E. Khalilipur","doi":"10.4103/rcm.rcm_67_21","DOIUrl":null,"url":null,"abstract":"Background: Transcatheter pulmonary valves (TPVs) are feasible and much less invasive options for surgical right ventricular outflow tract (RVOT) repair or valve replacement in patients with degeneration of the pulmonary valve bioprosthesis or RVOT conduit failure. In 2005, the first Sapien valve was implanted in the pulmonic position, and proceeding In March 2016, the Food and Drug Administration approved the SAPIEN valve (Edwards Lifesciences) for use in malfunctioning RVOT conduits. Material and method: We describe the first ten cases of TPV-in-valve procedure conducted in our center, along with the patients' prior surgical history, procedural details, and their clinical and echocardiographic data. Result and conclusion: Our data provided safety and efficacy of transcatheter valve-in-valve procedure in degenerated pulmonary bioprotheses and our follow-up proved durability of this procedure.","PeriodicalId":21031,"journal":{"name":"Research in Cardiovascular Medicine","volume":"11 1","pages":"13 - 19"},"PeriodicalIF":0.2000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research in Cardiovascular Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/rcm.rcm_67_21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Transcatheter pulmonary valves (TPVs) are feasible and much less invasive options for surgical right ventricular outflow tract (RVOT) repair or valve replacement in patients with degeneration of the pulmonary valve bioprosthesis or RVOT conduit failure. In 2005, the first Sapien valve was implanted in the pulmonic position, and proceeding In March 2016, the Food and Drug Administration approved the SAPIEN valve (Edwards Lifesciences) for use in malfunctioning RVOT conduits. Material and method: We describe the first ten cases of TPV-in-valve procedure conducted in our center, along with the patients' prior surgical history, procedural details, and their clinical and echocardiographic data. Result and conclusion: Our data provided safety and efficacy of transcatheter valve-in-valve procedure in degenerated pulmonary bioprotheses and our follow-up proved durability of this procedure.
rajaie心血管医疗研究中心首个10个经导管肺动脉瓣中瓣手术
背景:对于肺动脉瓣生物瓣膜退化或右心室流出道导管故障的患者,经导管肺动脉瓣(TPV)是可行的、侵入性小得多的手术右心室流出路(RVOT)修复或瓣膜置换的选择。2005年,第一个Sapien瓣膜被植入肺动脉位置,2016年3月,美国食品药品监督管理局批准Sapien瓣膜(Edwards Lifesciences)用于出现故障的RVOT导管。材料和方法:我们描述了在我们中心进行的瓣膜手术中的前10例TPV,以及患者以前的手术史、手术细节以及他们的临床和超声心动图数据。结果和结论:我们的数据提供了经导管瓣膜置换术治疗退化性肺生物瓣膜的安全性和有效性,我们的随访证明了该手术的耐用性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Research in Cardiovascular Medicine
Research in Cardiovascular Medicine CARDIAC & CARDIOVASCULAR SYSTEMS-
自引率
0.00%
发文量
13
审稿时长
17 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信